After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The disappointing Pynnacle trial is set to yield registrational data.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A single but durable stable disease sends the microcap's stock up 730%.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
A newly published cache of CRLs includes six novel oncology drugs.
